Conferences are great for CPD- much of what we hear isn’t immediately usable in our system.
Let experts distil it down😀
👇Join the brilliant @Paneeshas@VidhyaMurthy1 & others
I learnt a lot from both
Maybe they teach you a thing or two :)
#medicine#hematology#medtwitter
CELESTIAL-2 is official. Will present the TIP abstract at #ASCO26
Zanubrutinib plus Sonrotoclax (ZS) vs. Acalabrutinib plus Venetoclax for TN #CLL
What will be the best all oral FD treatment for CLL?
https://t.co/2IXGtqY6MG
@fredhutch
Join us for the Summer Congress Insights meeting in Birmingham on Friday 26th June. Updates from ASCO and EHA by leading clinicians in the field. A fantastic opportunity for networking too. For more details: https://t.co/ImgmE1UCRI
To register: https://t.co/velnBjLa13
Intriguing data from Luan et al. Time of CAR-T infusion may influence outcome.
• multicentre retrospect, 1052 pts
• rel / ref DLBCL
• med infn time 11.48am
• every hr later assoc with worse outcome
• 1y PFS 51% < 12pm, 35% > 12pm
#lymsm
https://t.co/D6j718GRqB
A massive thank you to everyone who bought tickets to my guitar raffle these past few weeks. Together you've raised over £50,000 for the Heartlands Hospital Charity appeal. What an incredible achievement and only possible thanks to all of you 🖤 - Tony
Keep an eye on your inbox for an email to the winner.
Pirtobrutinib is now approved for pts with #CLL after cBTKi.
Pirtobrutinib can now be used in second line, potentially.
Big #ASH25 for pirtobrutinib!
https://t.co/IBjAEJaQNV
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia | NEJM https://t.co/bJu6QFik18
Great work from UK Team! Undetectable MRD and extended progression-free survival were more common with ibrutinib–venetoclax than with ibrutinib alone
➡️➡️Big CLL news!
Munir et al
OS and PFS adv for MRD driven I&V over ibrutinib in 1L #CLL#EHA2025
Congrats to all FLAIR trial 🇬🇧group
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia | New England Journal of Medicine https://t.co/7Odds8kWZK